

Title (en)

SUSTAINED RELEASE ORAL DOSAGE FORM FOR NAPROXYN.

Title (de)

DOSIERUNGSFORM FÜR NAPROXYN FÜR DAUERVERABREICHUNG IM MUND.

Title (fr)

FORME DE DOSAGE ORALE A LIBERATION ENTRETENUE POUR NAPROXYN.

Publication

**EP 0178299 A4 19870428 (EN)**

Application

**EP 84901535 A 19840321**

Priority

US 8400431 W 19840321

Abstract (en)

[origin: WO8504099A1] Sustained release tablet and method for administration of (+)-6-methoxy-alpha-methyl-2-naphthaleneacetic acid over a prolonged period, a single administration of the sustained release tablet of the present invention providing a 24 hour administration of the drug. This oral sustained release dosage form is a tablet containing sufficient (+)-6-methoxy-alpha-methyl-2-naphthaleneacetic acid to provide a sustained release over a prolonged period contained in granules formed into said tablet, said tablet consisting essentially of a plurality of compressed granules consisting essentially of from about 1 to about 30 parts by weight hydroxypropyl methylcellulose and about 1 to about 30 parts by weight polyvinylpyrrolidone and a lubricant for the granules, such as magnesium stearate. The oral sustained release dosage unit form permits a sustained release of (+)-6-methoxy-alpha-methyl-2-naphthaleneacetic acid over a period of about 24 hours, eliminating the need for dosing at different periods of the day.

IPC 1-7

**A61K 9/22**; A61K 9/26; A61K 9/52; A61K 31/78

IPC 8 full level

**A61K 9/20** (2006.01); **A61K 9/22** (2006.01); **A61K 31/19** (2006.01)

CPC (source: EP)

**A61K 9/2027** (2013.01); **A61K 9/2054** (2013.01); **A61K 31/19** (2013.01)

Citation (search report)

- No relevant documents have been disclosed.
- See references of WO 8504099A1

Designated contracting state (EPC)

AT BE CH DE FR GB LI LU NL SE

DOCDB simple family (publication)

**WO 8504099 A1 19850926**; EP 0178299 A1 19860423; EP 0178299 A4 19870428

DOCDB simple family (application)

**US 8400431 W 19840321**; EP 84901535 A 19840321